Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Active Biotech AB ( (SE:ACTI) ) is now available.
Active Biotech AB announced the successful outcome of its rights issue, which was subscribed to approximately 82.8 percent, raising approximately SEK 70.3 million before issuing costs. This funding will support the company’s strategic focus on developing tasquinimod for myelofibrosis and advancing laquinimod for inflammatory eye diseases, ensuring the programs are fully funded until the end of 2027.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company is engaged in clinical development for hematological malignancies and inflammatory eye disorders, with key projects including tasquinimod for myelofibrosis and laquinimod for non-infectious uveitis.
YTD Price Performance: -38.37%
Average Trading Volume: 7,213,414
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK157.1M
For an in-depth examination of ACTI stock, go to TipRanks’ Overview page.